Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of DW4421 and DW4421S in Healthy Volunteers
NCT07364877Phase 1Enrolling by invitation
- Sponsor
- Daewon Pharm
- Start
- Dec 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DW4421-1 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewon Pharm. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Curve from time 0 to t at 48 hours. Started Dec 2025; status: enrolling by invitation.
02
Drugs
DW4421-1
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07364877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364877.